Sydney-headquartered neuroscience software developer Omniscient Neurotechnology (o8t) has received Therapeutic Goods Administration (TGA) clearance for its brain mapping platform Quicktome, along with clearance from the US FDA and Health Canada.

The technology, aimed at allowing neurosurgeons to visualise and understand a patient's brain networks prior to surgery, is part of the new field of ‘connectomics’, described as the understanding of brain connectivity in routine neurosurgical planning.